Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Fibrosis, and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CHI3L1/YKL40 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CHI3L1/YKL40 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CHI3L1 Products |
| Gene Delivery | CHI3L1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View CHI3L1 Products |
| Benchmark Ab | Anti-CHI3L1 Recombinant Monoclonal Antibody Recombinant positive control for assay validation. |
View CHI3L1 Products |
| Validator | CHI3L1 siRNA Set For knockdown verification in functional assays. |
View CHI3L1 Products |
| Related Target A | IL13RA2 Primary functional receptor for CHI3L1 mediating downstream MAPK/ERK activation. |
View IL13RA2 Products |
| Related Target B | TMEM219 Co-receptor partnering with IL13RA2 to mediate CHI3L1-induced cell survival and fibrotic pathways. |
View TMEM219 Products |
| Related Target C | AGER (RAGE) Alternative receptor interacting with CHI3L1 to drive inflammatory signaling. |
View AGER Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation Requirement | HEK293 host expression ensures correct folding and post-translational modifications of CHI3L1. |
| Receptor Binding Validation | Purified IL13RA2 and TMEM219 extracellular domain proteins available for robust ELISA/SPR binding assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included as positive controls. |
| False Positives | Validated siRNA sets included for target specificity knockdown checks. |
Live CHI3L1/YKL40 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CHI3L1/YKL40 therapeutics is intensifying, with major players shifting focus from traditional oncology mAbs to multi-targeted approaches in fibrotic diseases and severe asthma. As first-generation neutralizing antibodies enter early-phase clinical evaluation, the next wave of R&D is targeting the disruption of the CHI3L1-IL13RA2-TMEM219 signaling complex to reverse tumor immunosuppression and tissue remodeling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Neutralizing) | Elm Street Pharmaceuticals, OncoRex | Idiopathic Pulmonary Fibrosis (IPF), Glioblastoma, Severe Asthma | Receptor Blocking Assays (Need high-purity, native glycosylated CHI3L1 and IL13RA2/TMEM219 proteins) |
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Solid Tumors, Inflammatory Bowel Disease (IBD) | High-Throughput Binding Screening (Need sequence-verified, endotoxin-controlled recombinant proteins) |
| Combination Therapies (with PD-1/L1) | Oncology-focused Biotechs | Immune-refractory Solid Tumors | In vitro macrophage polarization assays (Need stable gene delivery via Lentivirus Premade Particles) |